GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sareum Holdings PLC (LSE:SAR) » Definitions » Profitability Rank

Sareum Holdings (LSE:SAR) Profitability Rank : 1 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Sareum Holdings Profitability Rank?

Sareum Holdings has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Sareum Holdings's Operating Margin % for the quarter that ended in Dec. 2023 was %. As of today, Sareum Holdings's Piotroski F-Score is 2.


Competitive Comparison of Sareum Holdings's Profitability Rank

For the Biotechnology subindustry, Sareum Holdings's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sareum Holdings's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sareum Holdings's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Sareum Holdings's Profitability Rank falls into.



Sareum Holdings Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Sareum Holdings has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Sareum Holdings's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-2.536 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Sareum Holdings has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Sareum Holdings Profitability Rank Related Terms

Thank you for viewing the detailed overview of Sareum Holdings's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Sareum Holdings (LSE:SAR) Business Description

Traded in Other Exchanges
Address
Langford Arch, London Road, Unit 2a, Pampisford, Cambridge, Cambridgeshire, GBR, CB22 3FX
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.

Sareum Holdings (LSE:SAR) Headlines

From GuruFocus